ArticleThe Journal of pediatrics2012
Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease.
Article in The Journal of pediatrics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 139 citations in OpenAlex.
- Effect and Safety of TNF Inhibitors in Immunoglobulin-Resistant Kawasaki Disease: a Meta-analysis.Clinical reviews in allergy & immunology · 2017Pooled it
- Yersinia pseudotuberculosis infection in Kawasaki disease and its clinical characteristics.BMC pediatrics · 2015Trial
- Knowledge framework of intravenous immunoglobulin resistance in the field of Kawasaki disease: A bibliometric analysis (1997-2023).Immunity, inflammation and disease · 2024Article
- Review
- Cyclosporine for the treatment of multisystem inflammatory syndrome in children with coronary artery aneurysms.BMJ case reports · 2022Article
- Kawasaki Disease: A Systematic Review and Meta-Analysis of Benefits and Harms of Common Treatments.ACR open rheumatology · 2021Article
- Predictive value of Albumin-Bilirubin grade for intravenous immunoglobulin resistance in a large cohort of patients with Kawasaki disease: a prospective study.Pediatric rheumatology online journal · 2021Article
- Epidemiology and Risk Factors for Giant Coronary Artery Aneurysms Identified After Acute Kawasaki Disease.Pediatric cardiology · 2021Article
- Predictive value of C-reactive protein to albumin ratio as a biomarker for initial and repeated intravenous immunoglobulin resistance in a large cohort of Kawasaki disease patients: a prospective cohort study.Pediatric rheumatology online journal · 2021Article
- 2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease.Current infectious disease reports · 2021Review
- MicroRNA-223 Regulates the Development of Cardiovascular Lesions in LCWE-Induced Murine Kawasaki Disease Vasculitis by Repressing the NLRP3 Inflammasome.Frontiers in pediatrics · 2021Article
- COVID-19 and multisystem inflammatory syndrome in children and adolescents.The Lancet. Infectious diseases · 2020Review
- Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease.Current opinion in pharmacology · 2020Review
- Kawasaki Disease: an Update.Current rheumatology reports · 2020Review
- Treatment-associated hemolysis in Kawasaki disease: association with blood-group antibody titers in IVIG products.Blood advances · 2020Article
- The elevated serum levels of calcineurin and nuclear factor of activated T-cells 1 in children with Kawasaki disease.Pediatric rheumatology online journal · 2020Article
- The role of CaScientific reports · 2020Article
- Antibodies and Immunity During Kawasaki Disease.Frontiers in cardiovascular medicine · 2020Review
- Predictive value of serum procalcitonin for both initial and repeated immunoglobulin resistance in Kawasaki disease: a prospective cohort study.Pediatric rheumatology online journal · 2019Article
- Predictors and management of intravenous immunoglobulin-resistant Kawasaki disease.Korean journal of pediatrics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
objectiveTo describe the clinical course and outcome of 10 patients with Kawasaki disease (KD) treated with a calcineurin inhibitor after failing to respond to multiple therapies. STUDY
designDemographic and clinical data were prospectively collected using standardized case report forms. T-cell phenotypes were determined by flow cytometry, and KD risk alleles in ITPKC (rs28493229), CASP3 (rs72689236), and FCGR2A (rs1801274) were genotyped.
resultsIntravenous followed by oral therapy with cyclosporine (CSA) or oral tacrolimus was well tolerated and resulted in defervescence and resolution of inflammation in all 10 patients. There were no serious adverse events, and a standardized treatment protocol was developed based on our experiences with this patient population. Analysis of T-cell phenotype by flow cytometry in 2 subjects showed a decrease in circulating activated CD8(+) and CD4(+) T effector memory cells after treatment with CSA. However, suppression of regulatory T-cells was not seen, suggesting targeting of specific, proinflammatory T-cell compartments by CSA.
conclusionTreatment of refractory KD with a calcineurin inhibitor appears to be a safe and effective approach that achieves rapid control of inflammation associated with clinical improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.